112 related articles for article (PubMed ID: 15285882)
1. Introduction to kidney dose-response for radionuclide therapy.
Sgouros G
Cancer Biother Radiopharm; 2004 Jun; 19(3):357-8. PubMed ID: 15285882
[No Abstract] [Full Text] [Related]
2. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
Denardo GL; Macey DJ
Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
[No Abstract] [Full Text] [Related]
3. Summary and perspectives on kidney dose-response to radionuclide therapy.
Wessels B
Cancer Biother Radiopharm; 2004 Jun; 19(3):388-90. PubMed ID: 15285887
[No Abstract] [Full Text] [Related]
4. Renal dosimetry in peptide radionuclide receptor therapy.
Siegel JA; Stabin MG; Sharkey RM
Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
[TBL] [Abstract][Full Text] [Related]
5. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy.
O'Donoghue J
Cancer Biother Radiopharm; 2004 Jun; 19(3):378-87. PubMed ID: 15285886
[TBL] [Abstract][Full Text] [Related]
6. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
Abou-Jaoudé W; Dale R
Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
[TBL] [Abstract][Full Text] [Related]
7. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.
Dale R
Cancer Biother Radiopharm; 2004 Jun; 19(3):363-70. PubMed ID: 15285884
[TBL] [Abstract][Full Text] [Related]
8. Horizons in radionuclide therapy: 1985 update.
Beierwaltes WH
J Nucl Med; 1985 Apr; 26(4):421-7. PubMed ID: 3884750
[TBL] [Abstract][Full Text] [Related]
9. A different approach to the use of unsealed radionuclides for cancer therapy.
McCready VR
Eur J Nucl Med; 1995 Jan; 22(1):1-3. PubMed ID: 7698148
[No Abstract] [Full Text] [Related]
10. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.
Green A; Flynn A; Pedley RB; Dearling J; Begent R
Cancer Biother Radiopharm; 2004 Jun; 19(3):371-7. PubMed ID: 15285885
[TBL] [Abstract][Full Text] [Related]
11. Radiotargeting agents for cancer therapy.
Kassis AI
Expert Opin Drug Deliv; 2005 Nov; 2(6):981-91. PubMed ID: 16296803
[TBL] [Abstract][Full Text] [Related]
12. Optimal therapeutic strategies for radioimmunotherapy.
O'Donoghue JA
Recent Results Cancer Res; 1996; 141():77-99. PubMed ID: 8722421
[No Abstract] [Full Text] [Related]
13. Outpatient administration of radiolabeled monoclonal antibodies.
Tuinstra N
Clin J Oncol Nurs; 2003; 7(1):106-8. PubMed ID: 12629945
[No Abstract] [Full Text] [Related]
14. Clinical aspects of radiation nephropathy.
Breitz H
Cancer Biother Radiopharm; 2004 Jun; 19(3):359-62. PubMed ID: 15285883
[TBL] [Abstract][Full Text] [Related]
15. [Kidney stress in percutaneous abdominal radiotherapy].
Schmidt N; Tkocz HJ; Leetz HK; Deveny A
Strahlentherapie; 1975 Apr; 149(4):378-83. PubMed ID: 1135895
[TBL] [Abstract][Full Text] [Related]
16. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
17. [Use of mathematical optimization in radiotherapy for deriving optimum irradiation procedures. II. Studies on application of hyperbolic and polyoptimization for improving relationship between focal dose and integral dose].
Franke DS
Radiobiol Radiother (Berl); 1980 Feb; 21(1):78-87. PubMed ID: 7465803
[No Abstract] [Full Text] [Related]
18. Radionuclide therapy of tumors: general aspects and considerations.
Hoefnagel CA
Int J Biol Markers; 1993; 8(3):172-9. PubMed ID: 8277209
[TBL] [Abstract][Full Text] [Related]
19. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry of internal emitters.
Sgouros G
J Nucl Med; 2005 Jan; 46 Suppl 1():18S-27S. PubMed ID: 15653648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
